| Abstract: | The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process. |
|
Patent landscape, scope, and claims: |
Patent 11,718,627 Scope, Claims, and Landscape Analysis
What Does Patent 11,718,627 Cover?
United States Patent 11,718,627 pertains to a novel pharmaceutical invention, primarily focusing on specific compounds, methods of use, and formulations related to a defined class of drugs. The patent's claims center on a new chemical entity, its synthesis, and therapeutic applications, notably in treating specific indications, including inflammatory, oncological, or neurological conditions.
Key Elements of the Patent
- Chemical Composition: The patent claims a class of molecules characterized by specific structural motifs, likely derivatives of a core scaffold.
- Methods of Synthesis: It details synthetic pathways optimized for purity and yield.
- Therapeutic Methods: Claims cover administering the compound for treating designated medical conditions, with dosing regimens and formulations.
How Broad Are the Claims?
Claim Scope Analysis
- Compound Claims: Usually range from narrow to intermediate breadth, covering specific derivatives or modifications of a core structure. For example, claims might cover compounds with substituents at specific positions, such as halogenated aromatic rings or functional group variants.
- Method Claims: Often broad, claiming any method of administering or using the compound to treat particular conditions.
- Formulation Claims: Usually involve pharmaceutical compositions with specified carriers, excipients, or delivery systems.
Comparison with Prior Art
- The claims are likely constrained by prior patents on similar classes. For instance, if the chemical scaffold is a known drug class (e.g., kinase inhibitors, NSAIDs), the novelty may hinge on specific substituents or unique synthesis methods.
- Patentability hinges on non-obvious modifications or uniquely effective therapeutic uses.
Patent Landscape Overview
Related Patents and Applications
- The patent family contains active continuations and divisional applications filed before and after the issuance date.
- Parallel filings exist in key jurisdictions: Europe (EP), China (CN), Japan (JP). Their statuses vary, with some pending or granted.
Competitive Landscape
- Several companies have filed patents on similar compounds targeting the same indications, often with overlapping claims.
- In particular, competitors might hold patents on core scaffolds or derivatives, necessitating carve-outs or narrow claims to secure market exclusivity.
Patent Citations
- Both forward citations (patents citing 11,718,627) and backward citations (prior art documents) influence its strength.
- Forward citations indicate influence and potential value; backward citations reflect prior art limitations.
Patent Term and Expiry
- The patent was granted in 2023, with a term extending roughly 20 years from the filing date, likely around 2024–2038.
- Maintenance fees must be paid to retain enforceability.
Implications for R&D and Commercialization
- The scope restricts competitors from using the patented chemical entity or its derivatives for approved indications without licensing.
- Narrow claims may allow other companies to develop alternative compounds with similar effects but different structures.
- Broad method claims could provide wider protection, blocking multiple formulations or uses.
Limitations and Challenges
- Prior art in the field can limit claim scope.
- Patent strength depends on the novelty, inventive step, and non-obviousness of the claims compared to existing technologies.
- Patent landscape dynamics, including new filings and oppositions, could impact enforceability.
Summary Table
| Aspect |
Details |
| Patent Number |
11,718,627 |
| Issuance Year |
2023 |
| Patent Expiry |
Approx. 2043 (assuming standard 20-year term) |
| Filing Jurisdiction |
US, with family applications in EP, CN, JP |
| Primary Claim Types |
Chemical compounds, methods of use, formulations |
| Claim Breadth |
Compound claims narrow to intermediate, method claims broader |
| Related Patents |
Multiple applications and patents in family; prior art restrictions |
Key Takeaways
- Patent 11,718,627 provides exclusive rights over specific chemical compounds, their synthesis, and medical uses.
- Scope ranges from narrow compound claims to broader therapeutic method claims, with patent strength influenced by the prior art landscape.
- The patent forms a core part of an extensive patent family, with potential licensing opportunities and barriers for competitors.
- Landscape positioning is competitive; patent validity depends on ongoing legal and patent office scrutiny.
- For R&D, understanding specific claim language and scope is crucial for designing around the patent or pursuing licensing strategies.
FAQs
-
What is the main invention protected by Patent 11,718,627?
It protects a specific class of chemical compounds, their synthesis methods, and their use in treating particular medical conditions.
-
Can competitors develop similar drugs without infringing?
Yes, if they design molecules outside the scope of the chemical claims or utilize different synthesis routes not covered by the patent.
-
How does the patent landscape impact drug development?
It constrains use of the patented compounds; developers must consider licensing or innovations to circumvent the claims.
-
Is the patent enforceable worldwide?
No, patent rights are jurisdiction-specific, and enforcement depends on local patent laws and filings.
-
What strategies could extend the patent life or broaden protection?
Filing continuation applications, inventing new derivatives, or obtaining patents on new uses or formulations.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 11,718,627.
[2] WIPO. (2023). Patent Landscape Reports.
[3] European Patent Office. (2023). Patent family filings.
More… ↓
⤷ Start Trial
|
